Amira Abugomaa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amira Abugomaa has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Elbadawy
Laboratory of Veterinary Pharmacology, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Japan
25 shared publications - Tatsuya Usui
Laboratory of Veterinary Pharmacology, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Japan
14 shared publications Yuta Shinohara
Pet Health & Food Division, Iskara Industry CO., LTD, 1-14-2, Nihonbashi, Chuo-ku, Tokyo, 103-0027, Japan
8 shared publicationsKazuaki Sasaki
Laboratory of Veterinary Pharmacology, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu, Tokyo 183-8509, Japan
6 shared publications- Kazuaki Sasaki
Laboratory of Veterinary Pharmacology, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu, Tokyo 183-8509, Japan
6 shared publications Megumi Yamanaka
Dept. Vet Med., Fac. agr., Tokyo Univ of Agr andTech
6 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13  (9) , 879
Modeling Canine Hemangiosarcoma Progression Using Patient-Derived 2.5D Organoids and Orthotopic Xenografts
Canine hemangiosarcoma (HSA) is a highly aggressive vascular malignancy encountered in veterinary practice and exhibits histopathological and molecular similarities to human angiosarcoma (AS). Despite its clinical importance, the molecular mechanisms driving canine HSA remain poorly understood, limiting the development of effective therapeutic approaches. To address this challenge, we established patient-derived canine HSA 2.5D organoids as a preclinical model. Following validation of lineage-specific marker expression, we evaluated drug responses and performed transcriptomic analyses comparing HSA organoids with nodular hyperplasia (NH) samples to identify molecular alterations associated with malignant transformation. Differential gene expression analysis revealed several genes enriched in HSA, including Phospholipase A and Acyltransferase 3 (PLAAT3), which was significantly upregulated in HSA organoids. Functional studies demonstrated that both siRNA-mediated silencing and pharmacological inhibition of PLAAT3 markedly reduced the invasive capacity of HSA organoid cells while exerting only modest effects on cell proliferation. In addition, orthotopic implantation of HSA 2.5D organoids into the spleens of immunodeficient mice generated xenograft tumors with metastatic behavior and histopathological features closely resembling those of the original canine tumors. Collectively, these results establish a canine HSA 2.5D organoid model and identify PLAAT3 as a candidate molecule associated with the invasive phenotype of canine HSA, providing a valuable platform for investigating disease biology and for future comparative studies of canine HSA and human AS.
- 27 August 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13  (9) , 879
Open AccessModeling Canine Hemangiosarcoma Progression Using Patient-Derived 2.5D Organoids and Orthotopic Xenografts
Canine hemangiosarcoma (HSA) is a highly aggressive vascular malignancy encountered in veterinary practice and exhibits histopathological and molecular similarities to human angiosarcoma (AS). Despite its clinical importance, the molecular mechanisms driving canine HSA remain poorly understood, limiting the development of effective therapeutic approaches. To address this challenge, we established patient-derived canine HSA 2.5D organoids as a preclinical model. Following validation of lineage-specific marker expression, we evaluated drug responses and performed transcriptomic analyses comparing HSA organoids with nodular hyperplasia (NH) samples to identify molecular alterations associated with malignant transformation. Differential gene expression analysis revealed several genes enriched in HSA, including Phospholipase A and Acyltransferase 3 (PLAAT3), which was significantly upregulated in HSA organoids. Functional studies demonstrated that both siRNA-mediated silencing and pharmacological inhibition of PLAAT3 markedly reduced the invasive capacity of HSA organoid cells while exerting only modest effects on cell proliferation. In addition, orthotopic implantation of HSA 2.5D organoids into the spleens of immunodeficient mice generated xenograft tumors with metastatic behavior and histopathological features closely resembling those of the original canine tumors. Collectively, these results establish a canine HSA 2.5D organoid model and identify PLAAT3 as a candidate molecule associated with the invasive phenotype of canine HSA, providing a valuable platform for investigating disease biology and for future comparative studies of canine HSA and human AS.
- Open Access
- 27 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (17) , 7681
Anti-Tumor Potential of Selective L-Type Amino Acid Transporter (LAT1) Inhibitor, JPH203, in Patient-Derived Canine Bladder Cancer Organoids
L-type amino acid transporter 1 (LAT1), which controls the neutral amino acid uptake across the cell membranes, has been frequently overexpressed in various human cancers. Overexpression of LAT1 is associated with higher proliferation and shorter patient survival in tumors. Here, upregulated LAT1 expression was observed in patient-derived canine bladder cancers (BCs), and a small-molecule LAT1 inhibitor (JPH203) successfully reduced BC tumor growth both in vitro and in vivo. Patient-derived cancer cells were collected from dogs with naturally occurring tumors at veterinary clinics in Japan, and the 2.5D cancer organoid culture system was generated following our previous studies. Compared with other canine cancers or normal bladder cells, the increased LAT1 expression was observed in 2 strains of BC organoids. JPH203 inhibited boronophenylalanine (BPA) uptake activity by more than 90% and suppressed cell proliferation dose-dependently. Deprivation of BPA uptake activity by JPH203 also regulated the phosphorylation of mTOR-related proteins. Furthermore, intraperitoneal administration of JPH203 decreased the growth and tumor weight of BC organoid-derived xenograft in immunodeficient mice with an induction of apoptosis and a decrease in LAT1 expression compared to vehicle-administered mice. Therefore, the present study demonstrates that JPH203 exerts anti-tumor effects in canine BC through modulation of the mTOR signaling pathway and supports further investigation of LAT1-targeted therapy for canine BC.
- 27 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (17) , 7681
Open AccessAnti-Tumor Potential of Selective L-Type Amino Acid Transporter (LAT1) Inhibitor, JPH203, in Patient-Derived Canine Bladder Cancer Organoids
L-type amino acid transporter 1 (LAT1), which controls the neutral amino acid uptake across the cell membranes, has been frequently overexpressed in various human cancers. Overexpression of LAT1 is associated with higher proliferation and shorter patient survival in tumors. Here, upregulated LAT1 expression was observed in patient-derived canine bladder cancers (BCs), and a small-molecule LAT1 inhibitor (JPH203) successfully reduced BC tumor growth both in vitro and in vivo. Patient-derived cancer cells were collected from dogs with naturally occurring tumors at veterinary clinics in Japan, and the 2.5D cancer organoid culture system was generated following our previous studies. Compared with other canine cancers or normal bladder cells, the increased LAT1 expression was observed in 2 strains of BC organoids. JPH203 inhibited boronophenylalanine (BPA) uptake activity by more than 90% and suppressed cell proliferation dose-dependently. Deprivation of BPA uptake activity by JPH203 also regulated the phosphorylation of mTOR-related proteins. Furthermore, intraperitoneal administration of JPH203 decreased the growth and tumor weight of BC organoid-derived xenograft in immunodeficient mice with an induction of apoptosis and a decrease in LAT1 expression compared to vehicle-administered mice. Therefore, the present study demonstrates that JPH203 exerts anti-tumor effects in canine BC through modulation of the mTOR signaling pathway and supports further investigation of LAT1-targeted therapy for canine BC.
- Open Access
- 6 April 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 162, 114651
Establishment of an experimental model of canine malignant mesothelioma organoid culture using a three-dimensional culture method
- 6 April 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 162, 114651
Open AccessEstablishment of an experimental model of canine malignant mesothelioma organoid culture using a three-dimensional culture method
- Open Access
- 4 September 2022
- Published by MDPI AG in Antibiotics
- Vol. 11  (9) , 1197
Phylotypic Profiling, Distribution of Pathogenicity Island Markers, and Antimicrobial Susceptibility of Escherichia coli Isolated from Retail Chicken Meat and Humans
Escherichia coli (E.coli) found in retail chicken meat could be causing a wide range of infections in humans and constitute a potential risk. This study aimed to evaluate 60 E. coli isolates from retail chicken meat (n = 34) and human urinary tract infections (UTIs, n = 26) for phylogenetic diversity, presence of pathogenicity island (PAI) markers, antimicrobial susceptibility phenotypes, and antimicrobial resistance genes, and to evaluate their biofilm formation capacity. In that context, confirmed E.coli isolates were subjected to phylogrouping analysis using triplex PCR, antimicrobial susceptibility testing using the Kirby–Bauer disc diffusion method; PAI distribution was investigated by using two multiplex PCRs. Most of the chicken isolates (22/34, 64.7%) were identified as commensal E. coli (A and B1), while 12 isolates (35.3%) were classified as pathogenic virulent E. coli (B2 and D). Similarly, the commensal group dominated in human isolates. Overall, 23 PAIs were detected in the chicken isolates; among them, 39.1% (9/23) were assigned to group B1, 34.8% (8/23) to group A, 4.34% (1/23) to group B2, and 21.7% (5/23) to group D. However, 25 PAIs were identified from the human isolates. PAI IV536 was the most prevalent (55.9%, 69.2%) PAI detected in both sources. In total, 37 (61.7%) isolates of the chicken and human isolates were biofilm producers. Noticeably, 100% of E. coli isolates were resistant to penicillin and rifamycin. Markedly, all E. coli isolates displayed multiple antibiotic resistance (MAR) phenotypes, and the multiple antibiotic resistance index (MARI) among E. coli isolates ranged between 0.5 and 1. Several antibiotic resistance genes (ARGs) were identified by a PCR assay; the sul2 gene was the most prevalent (38/60, 63.3%) from both sources. Interestingly, a significant positive association (r = 0.31) between biofilm production and resistance to quinolones by the qnr gene was found by the correlation analysis. These findings were suggestive of the transmission of PAI markers and antibiotic resistance genes from poultry to humans or humans to humans through the food chain. To avoid the spread of virulent and multidrug-resistant E. coli, intensive surveillance of retail chicken meat markets is required.
- 4 September 2022
- Published by MDPI AG in Antibiotics
- Vol. 11  (9) , 1197
Open AccessPhylotypic Profiling, Distribution of Pathogenicity Island Markers, and Antimicrobial Susceptibility of Escherichia coli Isolated from Retail Chicken Meat and Humans
Escherichia coli (E.coli) found in retail chicken meat could be causing a wide range of infections in humans and constitute a potential risk. This study aimed to evaluate 60 E. coli isolates from retail chicken meat (n = 34) and human urinary tract infections (UTIs, n = 26) for phylogenetic diversity, presence of pathogenicity island (PAI) markers, antimicrobial susceptibility phenotypes, and antimicrobial resistance genes, and to evaluate their biofilm formation capacity. In that context, confirmed E.coli isolates were subjected to phylogrouping analysis using triplex PCR, antimicrobial susceptibility testing using the Kirby–Bauer disc diffusion method; PAI distribution was investigated by using two multiplex PCRs. Most of the chicken isolates (22/34, 64.7%) were identified as commensal E. coli (A and B1), while 12 isolates (35.3%) were classified as pathogenic virulent E. coli (B2 and D). Similarly, the commensal group dominated in human isolates. Overall, 23 PAIs were detected in the chicken isolates; among them, 39.1% (9/23) were assigned to group B1, 34.8% (8/23) to group A, 4.34% (1/23) to group B2, and 21.7% (5/23) to group D. However, 25 PAIs were identified from the human isolates. PAI IV536 was the most prevalent (55.9%, 69.2%) PAI detected in both sources. In total, 37 (61.7%) isolates of the chicken and human isolates were biofilm producers. Noticeably, 100% of E. coli isolates were resistant to penicillin and rifamycin. Markedly, all E. coli isolates displayed multiple antibiotic resistance (MAR) phenotypes, and the multiple antibiotic resistance index (MARI) among E. coli isolates ranged between 0.5 and 1. Several antibiotic resistance genes (ARGs) were identified by a PCR assay; the sul2 gene was the most prevalent (38/60, 63.3%) from both sources. Interestingly, a significant positive association (r = 0.31) between biofilm production and resistance to quinolones by the qnr gene was found by the correlation analysis. These findings were suggestive of the transmission of PAI markers and antibiotic resistance genes from poultry to humans or humans to humans through the food chain. To avoid the spread of virulent and multidrug-resistant E. coli, intensive surveillance of retail chicken meat markets is required.
- Open Access
- 20 May 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 151, 113105
Establishment of an experimental model of normal dog bladder organoid using a three-dimensional culture method
- 20 May 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 151, 113105
Open AccessEstablishment of an experimental model of normal dog bladder organoid using a three-dimensional culture method
- Open Access
Prevalence and Characterization of PVL-Positive Staphylococcus aureus Isolated from Raw Cow’s Milk
The present study aimed to investigate the prevalence, antibiotic susceptibility profiles, and some toxin genes of Panton-Valentine leukocidin (PVL)-positive Staphylococcus aureus (S. aureus) in unpasteurized raw cow’s milk collected from retail outlets located at Mansoura, Dakahliya governorate, Egypt. In that context, a total of 700 raw cow’s milk samples were investigated for the presence of S. aureus, which was identified in 41.1% (288/700) of the samples. Among the S. aureus isolates, 113 PVL-positive S. aureus were identified and subjected for further analysis. The PVL-positive S. aureus were investigated for the existence of toxin-related genes, including hemolysin (hla), toxic shock syndrome toxin-1 (tst), and enterotoxins (sea, seb, sec, see, seg, sei, and selj). Genotypic resistance of PVL-positive strains was performed for the detection of blaZ and mecA genes. Among the PVL-positive S. aureus, sea, seb, and sec were detected in 44.2, 6.2%, and 0.9%, respectively, while the hla and tst genes were identified in 54.9% and 0.9%, respectively. The blaZ and mecA genes were successfully identified in 84.9 (96/113) and 32.7% (37/113) of the total evaluated S. aureus isolates, respectively. PVL-positive S. aureus displayed a high level of resistance to penicillin, ampicillin, and trimethoprim-sulfamethoxazole. Multidrug resistance (resistant to ≥3 antimicrobial classes) was displayed by all methicillin-resistant S. aureus (MRSA) and 38.2% of methicillin-sensitive S. aureus (MSSA) isolates. The obtained findings are raising the alarm of virulent PVL-positive MRSA clones in retail milk in Egypt, suggesting the requirement for limiting the use of β-lactam drugs in food-producing animals and the importance of implementing strong hygiene procedures in dairy farms and processing plants.
Open AccessPrevalence and Characterization of PVL-Positive Staphylococcus aureus Isolated from Raw Cow’s Milk
The present study aimed to investigate the prevalence, antibiotic susceptibility profiles, and some toxin genes of Panton-Valentine leukocidin (PVL)-positive Staphylococcus aureus (S. aureus) in unpasteurized raw cow’s milk collected from retail outlets located at Mansoura, Dakahliya governorate, Egypt. In that context, a total of 700 raw cow’s milk samples were investigated for the presence of S. aureus, which was identified in 41.1% (288/700) of the samples. Among the S. aureus isolates, 113 PVL-positive S. aureus were identified and subjected for further analysis. The PVL-positive S. aureus were investigated for the existence of toxin-related genes, including hemolysin (hla), toxic shock syndrome toxin-1 (tst), and enterotoxins (sea, seb, sec, see, seg, sei, and selj). Genotypic resistance of PVL-positive strains was performed for the detection of blaZ and mecA genes. Among the PVL-positive S. aureus, sea, seb, and sec were detected in 44.2, 6.2%, and 0.9%, respectively, while the hla and tst genes were identified in 54.9% and 0.9%, respectively. The blaZ and mecA genes were successfully identified in 84.9 (96/113) and 32.7% (37/113) of the total evaluated S. aureus isolates, respectively. PVL-positive S. aureus displayed a high level of resistance to penicillin, ampicillin, and trimethoprim-sulfamethoxazole. Multidrug resistance (resistant to ≥3 antimicrobial classes) was displayed by all methicillin-resistant S. aureus (MRSA) and 38.2% of methicillin-sensitive S. aureus (MSSA) isolates. The obtained findings are raising the alarm of virulent PVL-positive MRSA clones in retail milk in Egypt, suggesting the requirement for limiting the use of β-lactam drugs in food-producing animals and the importance of implementing strong hygiene procedures in dairy farms and processing plants.
- Open Access
- 1 January 2022
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 84  (6) , 841-846
Effect of the liquid form of traditional Chinese medicine, Hozen-S, on gastric motility in dogs
Juzen-taiho-to, a traditional Chinese herbal medicine, is used for patients with anorexia and fatigue in human medicine. In our previous study, granulated Juzen-taiho-to improved vincristine-induced gastrointestinal adverse effects through increasing gastric motility in dogs. As the effect of Hozen-S, the sweet liquid form of Juzen-taiho-to, on dog gastric motility has not been investigated, we examined the effect of administration of Hozen-S on gastric motility. Furthermore, we assessed dog plasma ghrelin level to further elucidate the mechanism of the effect of Hozen-S on gastric contraction. Finally, we assessed the palatability of Hozen-S compared to granulated Juzen-taiho-to and its effect on body weight in dogs. Administration of Hozen-S significantly increased gastric motility, plasma ghrelin concentration, and body weight. A palatability evaluation revealed that the dogs preferred Hozen-S to granulated Juzen-taiho-to. In conclusion, Hozen-S administration to dogs promoted gastric motility by raising plasma ghrelin levels. Considering these functional and palatability data, Hozen-S may replace granulated type Juzen-taiho-to and become a prominent traditional Chinese veterinary medicament.
- 1 January 2022
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 84  (6) , 841-846
Open AccessEffect of the liquid form of traditional Chinese medicine, Hozen-S, on gastric motility in dogs
Juzen-taiho-to, a traditional Chinese herbal medicine, is used for patients with anorexia and fatigue in human medicine. In our previous study, granulated Juzen-taiho-to improved vincristine-induced gastrointestinal adverse effects through increasing gastric motility in dogs. As the effect of Hozen-S, the sweet liquid form of Juzen-taiho-to, on dog gastric motility has not been investigated, we examined the effect of administration of Hozen-S on gastric motility. Furthermore, we assessed dog plasma ghrelin level to further elucidate the mechanism of the effect of Hozen-S on gastric contraction. Finally, we assessed the palatability of Hozen-S compared to granulated Juzen-taiho-to and its effect on body weight in dogs. Administration of Hozen-S significantly increased gastric motility, plasma ghrelin concentration, and body weight. A palatability evaluation revealed that the dogs preferred Hozen-S to granulated Juzen-taiho-to. In conclusion, Hozen-S administration to dogs promoted gastric motility by raising plasma ghrelin levels. Considering these functional and palatability data, Hozen-S may replace granulated type Juzen-taiho-to and become a prominent traditional Chinese veterinary medicament.
- Open Access
- 1 January 2022
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 95, 1-068
Effect of the liquid form of traditional Chinesemedicine, Hozen-S, on gastric motility in dog
Juzen-taiho-to, a traditional Chinese herbal medicine, is used for patients withanorexia and fatigue in human medicine. In our previous study, a granulated formof Juzen-taiho-to improved vincristine-induced gastrointestinal adverse effectsthrough increasing gastric motility in dogs. However, the effect of Hozen-S, thesweet liquid form of Juzen-taiho-to, on dog gastric motility has not beeninvestigated. Therefore, we examined whether the administration of Hozen-S todogs affects their gastric motility. To further elucidate the mechanism of theeffect of Hozen-S on gastric contraction, we assessed the plasma ghrelin levelof the dog. Finally, we assessed the Hozen-S palatability compared to granulatedJuzen-taiho-to in dogs and the effect on body weight in dogs. Administration ofHozen-S significantly increased gastric motility, plasma ghrelin concentration,and body weight in the dogs. As a result of the palatability evaluation, thesedogs preferred Hozen-S to the granulated Juzen-taiho-to. In conclusion, Hozen-Sadministration to dogs promoted gastric motility by raising the plasma ghrelinlevel. Considering these functional and palatability data, Hozen-S might replacethe granulated type Juzen-taiho-to and become a prominent traditional Chineseveterinary medicament.
- 1 January 2022
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 95, 1-068
Open AccessEffect of the liquid form of traditional Chinesemedicine, Hozen-S, on gastric motility in dog
Juzen-taiho-to, a traditional Chinese herbal medicine, is used for patients withanorexia and fatigue in human medicine. In our previous study, a granulated formof Juzen-taiho-to improved vincristine-induced gastrointestinal adverse effectsthrough increasing gastric motility in dogs. However, the effect of Hozen-S, thesweet liquid form of Juzen-taiho-to, on dog gastric motility has not beeninvestigated. Therefore, we examined whether the administration of Hozen-S todogs affects their gastric motility. To further elucidate the mechanism of theeffect of Hozen-S on gastric contraction, we assessed the plasma ghrelin levelof the dog. Finally, we assessed the Hozen-S palatability compared to granulatedJuzen-taiho-to in dogs and the effect on body weight in dogs. Administration ofHozen-S significantly increased gastric motility, plasma ghrelin concentration,and body weight in the dogs. As a result of the palatability evaluation, thesedogs preferred Hozen-S to the granulated Juzen-taiho-to. In conclusion, Hozen-Sadministration to dogs promoted gastric motility by raising the plasma ghrelinlevel. Considering these functional and palatability data, Hozen-S might replacethe granulated type Juzen-taiho-to and become a prominent traditional Chineseveterinary medicament.
- Top Cited PapersOpen Access
- 9 December 2021
- Published by Elsevier in Materials Today Bio
- Vol. 13, 100186
Smart/stimuli-responsive hydrogels: Cutting-edge platforms for tissue engineering and other biomedical applications
- 9 December 2021
- Published by Elsevier in Materials Today Bio
- Vol. 13, 100186
Top Cited PapersOpen AccessSmart/stimuli-responsive hydrogels: Cutting-edge platforms for tissue engineering and other biomedical applications
- Open Access
- 1 November 2021
- Published by ResearchersLinks Ltd in Advances in Animal and Veterinary Sciences
- Vol. 9  (12)
The Antinociceptive and Antipyretic Potentials of Cefepime
| The present study aimed to evaluate the analgesic and antipyretic potentials of cefepime at different therapeutic doses in vivo using hot-plate and brewer’s yeast-induced fever models in mice and rats, respectively. Twenty-five mice and/or rats were assigned into five groups, each of five animals. The first group of each was left as control and administered saline i.m. The second group was given ketoprofen (13 mg.) or metamizole sodium (150 mg) per kg BW i.m. as a standard analgesic and antipyretic, respectively. The third, fourth, and fifth groups were given cefepime at the different therapeutic doses, respectively, i.m. in saline. Cefepime induced dose-dependent and significant analgesic effect along the four h of the experiment which was indicated by the longer reaction time in treated than the control group. Cefepime at 45 mg/kg. BW had no antipyretic activity, while at 90 and 180 mg/kg BW had an antipyretic effect after 3.5 h of cefepime administration and at 180 mg/kg BW had a significant antipyretic potential 2.5 h after its injection. These findings indicate that cefepime possesses significant analgesic and antipyretic potentials that would be valuable in symptomatic relief of nociception and fever besides its well-established antibacterial effect.
- 1 November 2021
- Published by ResearchersLinks Ltd in Advances in Animal and Veterinary Sciences
- Vol. 9  (12)
Open AccessThe Antinociceptive and Antipyretic Potentials of Cefepime
| The present study aimed to evaluate the analgesic and antipyretic potentials of cefepime at different therapeutic doses in vivo using hot-plate and brewer’s yeast-induced fever models in mice and rats, respectively. Twenty-five mice and/or rats were assigned into five groups, each of five animals. The first group of each was left as control and administered saline i.m. The second group was given ketoprofen (13 mg.) or metamizole sodium (150 mg) per kg BW i.m. as a standard analgesic and antipyretic, respectively. The third, fourth, and fifth groups were given cefepime at the different therapeutic doses, respectively, i.m. in saline. Cefepime induced dose-dependent and significant analgesic effect along the four h of the experiment which was indicated by the longer reaction time in treated than the control group. Cefepime at 45 mg/kg. BW had no antipyretic activity, while at 90 and 180 mg/kg BW had an antipyretic effect after 3.5 h of cefepime administration and at 180 mg/kg BW had a significant antipyretic potential 2.5 h after its injection. These findings indicate that cefepime possesses significant analgesic and antipyretic potentials that would be valuable in symptomatic relief of nociception and fever besides its well-established antibacterial effect.